



Bal Pharma Limited

To,
The Manager-Listing
National Stock Exchange of India Ltd
Mumbai.

03/06/2019

BSE Limited
Mumbai.

Dear Sir,

Ref : Compliance with Regulation 47 of SEBI (LODR) Regulations , 2015.

With reference to the above, we are submitting to the exchange published audited financial results of the Company for the quarter and year ended 31/03/2019, in Financial Express (English) and Sanjay vani (vernacular), on 01st June 2019.

Please take the same on record.

Thanking You.

For Bal Pharma Ltd

Authorised Signatory.



ಪ್ರಾಚೀನ ವಿಭಾಗದಲ್ಲಿ ಉತ್ಕರ್ಷ, ವೈಚಾರಿಕ
ವಿವರಣೆ ವಿವರ ವಿಭಾಗದಲ್ಲಿ ಚರ್ಚೆ

Particulars		Standards				(Rs Lakhs ended on)	
		Quarter ended 31.03.2019 Audited	Quarter ended 31.03.2018 Unaudited	Quarter ended 31.03.2019 Unaudited	Quarter ended 31.03.2018 Unaudited	Year ended 31.03.2019 Audited	Year ended 31.03.2018 Audited
Total income from operations		573.41	564.63	573.53	2275.61	2259.31	2137.53
Net Profit (Loss) for the period, Before Tax, Extraordinary items and Extraordinary items		112.98	31.51	253.25	419.34	414.5	233.22
Net Profit (Loss) for the period before tax (After extraordinary and extraordinary items)		145.26	31.51	265.25	419.34	419.3	282.25
Net Profit (Loss) for the period after tax		157.12	17.33	117.58	554.52	554.26	171.5
Total comprehensive income for the period		335.74	17.33	163.54	553.41	172.35	171.5
Equity share capital		1417.24	1417.24	1417.24	1417.24	1417.24	1417.24
Other Equity Reserves		-	-	-	658.71	525.23	531.53
Balance, at the end of the period for continuing and discontinued activities		1584.98	1434.48	1584.98	1584.98	1584.98	1584.98

	ಸ್ವಲ್ಪಕಾಲೇಶ್	ಕನ್ಯಾಕೇಶ್

[illegible][illegible][illegible]